TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

INTERPHARM

Infectious DiseaseOncologyCardiovascular
Generics

INTERPHARM is a generic drug manufacturer focused on Infectious Disease, Oncology, Cardiovascular.

1987
Since
7
Drugs
-
Trials
113
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

DOXYCYCLINE HYCLATE 2026-02-19
SULFAMETHOXAZOLE AND TRIMETHOPRIM 2026-02-10
Labeling
DOXYCYCLINE HYCLATE 2026-02-06
Labeling
DOXYCYCLINE HYCLATE 2026-02-06
Labeling
PROPRANOLOL HYDROCHLORIDE 2026-01-27
DOXYCYCLINE HYCLATE 2026-01-26
Labeling
DOXYCYCLINE HYCLATE 2026-01-20
Labeling
DOXYCYCLINE HYCLATE 2026-01-20
Labeling
DOXYCYCLINE HYCLATE 2026-01-18
Labeling
DOXYCYCLINE HYCLATE 2025-12-09
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 31%
1 drugs Phase 3: 1 Phase 2: 2
Oncology 31%
0 drugs Phase 3: 3 Phase 1: 2
Cardiovascular 13%
1 drugs
Neurology 13%
1 drugs
Dermatology 11%
0 drugs Phase 3: 1 Phase 1: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Baxter specialty
Infectious Disease, Cardiovascular, Oncology, Dermatology
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
COSETTE other
Cardiovascular, Dermatology, Infectious Disease, Oncology
GE HEALTHCARE specialty
Infectious Disease, Neurology, Cardiovascular, Oncology
FOUGERA PHARMS other
Dermatology, Infectious Disease, Oncology, Cardiovascular